Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
HOME > REGULATORY
REGULATORY
- Kaketsuken in Talks with “Several Entities” over Possible Biz Transfer: New Chief
September 21, 2017
- MHLW to Consider Use of New Comprehensive Test System to Promote Practical Use of Genomic Medicine for Cancer: Official
September 21, 2017
- MHLW Issues Notification on Drug Criteria for Optimal Use Guidelines
September 20, 2017
- Japan Drug Spending Logs 1st Fall in FY2016
September 19, 2017
- MHLW Begins Discussions towards Submission of Bill to Amend Pharma Law in 2019: Official
September 19, 2017
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
- Chuikyo Working to Craft ICER Yardstick for Pilot CEA Scheme; Shiroiwa Study Leading Candidate among WTP Cost Surveys?
September 14, 2017
- Chuikyo Ponders How to Deal with ICER for Products with Multiple Indications
September 14, 2017
- Samurai Biotech Association Calls for NHI Price Increases When Sales Fall Below Forecasts: Chuikyo
September 14, 2017
- JGA President Sees Reduction in Number of Generic Drug Makers as “Inevitable”: Chuikyo
September 14, 2017
- With 253 Billion Yen Estimate Out, Chuikyo Members Prod MHLW to Vet Impact of Price Maintenance Premium
September 14, 2017
- JPWA Expresses Concern Over Price Renegotiations, Calls for Guidelines to Curb Practice
September 14, 2017
- (Update) Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
- MHLW to Notify of Criteria for Drugs Subject to Optimal Use Guidelines in Mid-September
September 13, 2017
- Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
- MHLW Calls for Reduction in Maximum Administration Period and Total Dosage for Feron
September 13, 2017
- MOF Budget Examiner Questions Price Maintenance Premium, Says Its Impact Amounts to Over 253 Billion Yen in FY2017
September 12, 2017
- MHLW to Draft GL on Use of Real World Data in Application Filings to Promote Development of Drugs for Rare Diseases
September 12, 2017
- Kyorin’s Dimethyl Sulfoxide Gets Orphan Status in Japan
September 11, 2017
- MHLW Panel Backs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med and More
September 11, 2017
ページ
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…